Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects. [electronic resource] by
- Wynne, Christopher
- Altendorfer, Mario
- Sonderegger, Ivo
- Gheyle, Lien
- Ellis-Pegler, Rod
- Buschke, Susanne
- Lang, Benjamin
- Assudani, Deepak
- Athalye, Sandeep
- Czeloth, Niklas
Producer: 20170310
In:
Expert opinion on investigational drugs vol. 25
Availability: No items available.
|